Volume 32, Issue 1 pp. 19-27
Article

CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma

Dana Nojima

Dana Nojima

Departments of Urology, Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California

Search for more papers by this author
Koichi Nakajima

Koichi Nakajima

Departments of Urology, Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California

Search for more papers by this author
Long-Cheng Li

Long-Cheng Li

Departments of Urology, Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California

Search for more papers by this author
Joseph Franks

Joseph Franks

Departments of Urology, Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California

Search for more papers by this author
Leopoldo Ribeiro-Filho

Leopoldo Ribeiro-Filho

Departments of Urology, Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California

Search for more papers by this author
Nobuhisa Ishii

Nobuhisa Ishii

Departments of Urology, Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California

Search for more papers by this author
Rajvir Dahiya

Corresponding Author

Rajvir Dahiya

Departments of Urology, Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California

Urology Research Center (112F), University of California San Francisco and VA Medical Center, 4150 Clement Street, San Francisco, CA 94121.Search for more papers by this author
First published: 10 September 2001
Citations: 50

Abstract

CpG methylation in the promoter region has been shown to be important in the regulation of genes implicated in malignant transformation. The present study was designed to test the hypothesis that CpG methylation of the promoter region of the E-cadherin gene may inactivate its expression in renal cell carcinoma. To test this hypothesis, five kidney cancer cell lines and 34 microdissected renal cell carcinoma samples were analyzed for gene and protein expression by reverse transcription–polymerase chain reaction and immunohistochemistry, respectively. CpG methylation in the promoter regions of the E-cadherin gene was analyzed by the sodium bisulfite genome sequencing technique. Our results show that all normal renal tissue expressed the E-cadherin gene and protein. Of the renal cancer tissues analyzed, 67% (23 of 34) lacked E-cadherin expression, with an associated increase in methylation, compared with normal tissue. E-cadherin gene promoter was methylated in all renal cancer cell lines and was accompanied by a loss of E-cadherin gene and protein expression. The treatment of renal cancer cell lines with the demethylating agent 5-aza-2′-deoxycytidine restored E-cadherin mRNA expression in all renal cancer cell lines. This is the first report that shows inactivation of the E-cadherin gene and protein in renal cell carcinoma through CpG hypermethylation in the promoter region of this gene. The results of these experiments may contribute to an understanding of the role of E-cadherin inactivation in renal cell carcinoma. © 2001 Wiley-Liss, Inc.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.